open access

Vol 5, No 6 (2016)
Case reports
Published online: 2017-03-31
Get Citation

Amelioration of liver function and glucose control with pioglitazone in a patient with diabetes mellitus type 2 and nonalcoholic fatty liver disease

Katarzyna Nabrdalik, Patrycja Pokrzywnicka, Diana Nabrdalik-Leśniak, Jakub Gumprecht, Hanna Kwiendacz, Janusz Gumprecht
DOI: 10.5603/DK.2016.0034
·
Clinical Diabetology 2016;5(6):199-202.

open access

Vol 5, No 6 (2016)
Case reports
Published online: 2017-03-31

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of hepatic steatosis and elevated ami­notransferases in the general population. It is a benign disease; however, in a portion of patients it progresses to nonalcoholic steatohepatitis (NASH) and cirrhosis. The most effective but the most difficult treatment for it is body mass reduction by behavior interventions. Different drugs have been tested in the treatment of NAFLD but their effect was not satisfactory; therefore, there is no regular, causal and pharmacological treatment for NAFLD at the moment. The etiology of NAFLD is unclear but insulin resistance is believed to play a significant pathogenic role. Data concerning the possibilities of using oral antidiabetic drugs in the treatment of NAFLD are limited. Among insulin sensitizers, metformin is a first-line drug in the treatment of diabetes type 2; however, due to its gastro-intestinal adverse reactions, some patients cannot use it or can­not achieve an optimal treatment dose. On the other hand, the drug is contraindicated for some patients. In this case study, we present a patient with diabetes mellitus type 2 with elevated aminotransferases levels related to NAFLD and inadequate glucose control, who has been treated with a sulphonylurea derivative and dipeptydylo peptidase IV inhibitor. Replacement of previously used drugs by basal insulin and pioglitazone resulted in both the reduction of the activity of liver enzymes and the improvement in glucose control.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of hepatic steatosis and elevated ami­notransferases in the general population. It is a benign disease; however, in a portion of patients it progresses to nonalcoholic steatohepatitis (NASH) and cirrhosis. The most effective but the most difficult treatment for it is body mass reduction by behavior interventions. Different drugs have been tested in the treatment of NAFLD but their effect was not satisfactory; therefore, there is no regular, causal and pharmacological treatment for NAFLD at the moment. The etiology of NAFLD is unclear but insulin resistance is believed to play a significant pathogenic role. Data concerning the possibilities of using oral antidiabetic drugs in the treatment of NAFLD are limited. Among insulin sensitizers, metformin is a first-line drug in the treatment of diabetes type 2; however, due to its gastro-intestinal adverse reactions, some patients cannot use it or can­not achieve an optimal treatment dose. On the other hand, the drug is contraindicated for some patients. In this case study, we present a patient with diabetes mellitus type 2 with elevated aminotransferases levels related to NAFLD and inadequate glucose control, who has been treated with a sulphonylurea derivative and dipeptydylo peptidase IV inhibitor. Replacement of previously used drugs by basal insulin and pioglitazone resulted in both the reduction of the activity of liver enzymes and the improvement in glucose control.

Get Citation

Keywords

diabetes type 2, NAFLD, NASH, pioglitazone

About this article
Title

Amelioration of liver function and glucose control with pioglitazone in a patient with diabetes mellitus type 2 and nonalcoholic fatty liver disease

Journal

Clinical Diabetology

Issue

Vol 5, No 6 (2016)

Pages

199-202

Published online

2017-03-31

DOI

10.5603/DK.2016.0034

Bibliographic record

Clinical Diabetology 2016;5(6):199-202.

Keywords

diabetes type 2
NAFLD
NASH
pioglitazone

Authors

Katarzyna Nabrdalik
Patrycja Pokrzywnicka
Diana Nabrdalik-Leśniak
Jakub Gumprecht
Hanna Kwiendacz
Janusz Gumprecht

References (17)
  1. Milić S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis. 2012; 30(2): 158–162.
  2. Wree A, Broderick L, Canbay A, et al. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013; 10(11): 627–636.
  3. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003; 37(6): 1286–1292.
  4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6): 2005–2023.
  5. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004; 126(2): 460–468.
  6. Targher G, Bertolini L, Padovani R, et al. Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients. Diabetes Care. 2007; 30(5): 1212–1218.
  7. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014; 46(4): 352–356.
  8. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology. 2013; 57(6): 2525–2531.
  9. Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol. 2013; 10(11): 637–644.
  10. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014; 59(2): 713–723.
  11. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005; 48(4): 634–642.
  12. Malinowski SS, Byrd JS, Bell AM, et al. Pharmacologic therapy for nonalcoholic fatty liver disease in adults. Pharmacotherapy. 2013; 33(2): 223–242.
  13. Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia. 2016; 59(6): 1112–1120.
  14. Rakoski MO, Singal AG, Rogers MAM, et al. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2010; 32(10): 1211–1221.
  15. Choudhary NS, Saraf N, Saigal S, et al. Rapid Reversal of Liver Steatosis With Life Style Modification in Highly Motivated Liver Donors. J Clin Exp Hepatol. 2015; 5(2): 123–126.
  16. Hallsworth K, Thoma C, Hollingsworth KG, et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clin Sci (Lond). 2015; 129(12): 1097–1105.
  17. Cohen DE, Anania FA, Chalasani N, et al. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006; 97(8A): 77C–81C.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl